New drug BL-B16D1 enters human trials for Hard-to-Treat cancers

NCT ID NCT06493864

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing a new drug called BL-B16D1 in 21 people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The main goals are to check safety, find the right dose, and get a first look at whether it might shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B16D1 (a drug given by IV infusion every 3 weeks)
What this could lead to: If it works, this could point toward a new treatment option for advanced breast cancer and other solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 21 participants, so it is primarily testing safety and dosing. The drug may not prove effective, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, China

Contact

Contact

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.